73387-52-7

Basic information

• Product Name: 5-(4-BROMOPHENYL)-1-METHYL-1H-PYRAZOLE
• Synonyms: 5-(4-BROMOPHENYL)-1-METHYL-1H-PYRAZOLE;5-(4-Bromophenyl)-1-methylpyrazole
• CAS NO: 73387-52-7
• Molecular Formula: C₁₀H₉BrN₂
• Molecular Weight: 237.11
• Mol File: 73387-52-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 58℃
• Boiling Point: 331.6 °C at 760 mmHg
• Flash Point: 154.4 °C
• Appearance: /
• Density: 1.44±0.1 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.000297mmHg at 25°C
• Refractive Index: 1.625
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 1.69±0.10(Predicted)
• CAS DataBase Reference: 5-(4-BROMOPHENYL)-1-METHYL-1H-PYRAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-BROMOPHENYL)-1-METHYL-1H-PYRAZOLE(73387-52-7)
• EPA Substance Registry System: 5-(4-BROMOPHENYL)-1-METHYL-1H-PYRAZOLE(73387-52-7)

Safety Data

• Hazardous Substances Data: 73387-52-7(Hazardous Substances Data)

Usage

General Description

5-(4-Bromophenyl)-1-methyl-1H-pyrazole is a chemical compound with the molecular formula C10H8BrN3. It is a pyrazole derivative that contains a bromophenyl group and a methyl substituent. 5-(4-Bromophenyl)-1-methyl-1H-pyrazole is commonly used in research and pharmaceutical applications, particularly in the development of new drugs. It is known for its potential activities as a bioactive compound, and it has been studied for its potential therapeutic effects in various medical conditions. The specific chemical properties and potential uses of 5-(4-Bromophenyl)-1-methyl-1H-pyrazole are subject to ongoing research and investigation in the scientific community.

InChI:InChI=1/C10H9BrN2/c1-13-10(6-7-12-13)8-2-4-9(11)5-3-8/h2-7H,1H3

Upstream product

• 73387-60-7 (2E)-1-(4-bromophenyl)-3-(dimethylamino)prop-2-en-1-one 
• 60-34-4 methylhydrazine 
• 99-90-1 para-bromoacetophenone 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 73387-60-7 1-(4-bromophenyl)-3-(dimethylamino)prop-2-en-1-one 
• 73387-46-9 3-(4-bromophenyl)-1H-pyrazole 
• 74-88-4 methyl iodide 

Downstream Products

• 1029317-21-2 4-(3-([4-(1-methyl-1H-pyrazol-5-yl)phenyl]thio)phenyl)tetrahydro-2H-pyran-4-carboxamide 
• 1159186-51-2 1-methyl-5-{4-[(triisopropylsilyl)thio]phenyl}-1H-pyrazole 
• 1159186-54-5 4-(1-methyl-1H-pyrazol-5-yl)benzenethiol 
• 1331755-98-6 C₂₄H₂₈N₂O₄S 
• 1381948-29-3 1-methyl-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole 
• 179055-28-8 4-(1-methylpyrazol-5-yl)benzaldehyde 

Relevant articles and documents

2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS

The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; X1 and X2 are independently, at each occurrence, CR5 or N; Y is C1-C6 alkylene, wherein alkylene is optionally substituted with one to two C1-C3 alkyl groups; R1 is selected from the group consisting of hydrogen, halogen, C1-C6 alkoxy, -NH2, -NHR6, -NR7R8 and -NH-(R9)n-R10, n being 0 or 1; R2 is selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, -NH2, -NHR6, - NR7R8 and -NH-(R9)n-R10; R3 is selected from the group consisting of hydrogen, hydroxyl, OR11, -NR7R8, C1-C6 alkoxy, C1-C6 alkyl, C3-C10 cycloalkyl, C1-C3 haloalkyl, -C(O)NHR11, aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four Ra groups; and R4 is selected from the group consisting of -NH2, -N(R12)(V)pR13, - NH(V)p-OR14, -NHC(O)R15, and groups of formula la shown below, and their use in the treatment of diseases, in particular inflammatory diseases, cancer, stroke and/or Alzheimer's disease.

NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A

The present invention relates to compounds of the formula I and their salts etc. which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders. wherein Y1 and Y2 are adjacent atoms in Het1, which are independently selected from the group consisting of carbon and nitrogen; k is 0, 1, 2 or 3; Het1 is a bivalent monocyclic 5- or 6-membered heteroaromatic radical, having 1, 2 or 3 heteroatoms or heteroatom moieties selected from O, S, N and N—Ra as ring members, or a bivalent fused bicyclic 8-, 9- or 10-membered heteroaromatic radical, having 1, 2, 3 or 4 heteroatoms or heteroatom moieties selected from O, S, N and N—Ra as ring members; Het2 is inter alia monocyclic 5- or 6-membered hetaryl, having 1, 2 or 3 heteroatoms or heteroatom moieties selected from O, S, N and N—R1a as ring members, Cyc is inter alia optionally substituted monocyclic 5- or 6-membered hetaryl or optionally substituted fused 8-, 9- or 10-membered bicyclic hetaryl; Ar is optionally substituted phenylene or optionally substituted bivalent 6-membered hetaryl; R is attached to a carbon atom of Het1 and inter alia-halogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, C1-C6-fluoroalkyl, C1-C6-fluoroalkoxy, C3-C6-cycloalkyl etc.

PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS

The invention relates to compounds of formula (I) processes for their preparation, their use as 5-lipoxygenase inhibitors and pharmaceutical compositions containing the same.